16th World Conference on Lung Cancer CME Accreditation

16th World Conference on Lung Cancer CME Accreditation

WCLC 2015

CME Accreditation

This activity is planned for AMA PRA Category 25.5 Credit(s)™.

How to get your CME Certificate / Certificate of Attendance

  • Click here >>
  • Complete Conference evaluation (mandatory)
  • When prompted, select CME Certificate/Certificate of Attendance and enter your email address and family name as used in the registration process

Important Note: The number of credits provided in your certificate are based on the actual sessions you attended and that you have been scanned for.

Please Note: Select and provide the sessions attended but not scanned so that your CME record can be updated.

For any questions, please contact Pia Hirsch.


Lung Cancer is the leading cause of death worldwide. Despite intensive research efforts to discover more effective treatment regimens, the survival rates for lung cancer remain low. However, progress has been and will continue to be made because of clinical, translational and basic research, all of which increases our overall knowledge and understanding of lung cancer. Screening with low-dose CT scans now offers the promise of early detection and the ever expanding identification of genetic abnormalities along with the development of molecularly-targeted agents bring personalized lung cancer treatment to the forefront. The World Conference addresses the importance of tobacco control in reducing the morbidity and mortality associated with lung cancer. The World Conference also provides a forum for the dissemination of the latest research findings to help physicians and researchers in lung cancer remain current on the optimum treatment approaches for individuals with lung cancer and other thoracic malignancies, as well as on issues related to prevention, early detection, imaging, staging according to the new IASLC staging system, pathology, molecular testing, palliative care, and patient advocacy.

Unlabelled Usage Statements

The information presented at the World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Official Language

The official language of the 16th World Conference on Lung Cancer is English.

Learning Objectives

At the end of the Conference the attendee will be able to:

  • Identify effective global lung cancer prevention strategies.
  • Improve their ability to participate in tobacco control and smoking cessation programs.
  • Describe the current approaches and strategies for early detection and screening of lung cancer.
  • Describe the best methods to implement multi-disciplinary tumor boards into community practices.
  • Describe evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
  • Describe evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
  • Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
  • Recognize the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
  • Understand the molecular pathways that hold promise for therapeutic intervention.
  • Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
  • Describe current therapeutic approaches for patients with mesothelioma and thymoma.
  • Define optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
  • Describe the support and survivorship resources available for lung cancer patients and their families.
  • Illustrate important aspects of clinical trial design and master protocols.
  • Educate more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.